Silvia Dellapasqua, Kathryn P Gray, Elisabetta Munzone, Daniela Rubino, Lorenzo Gianni, Harriet Johansson, Giuseppe Viale, Karin Ribi, Jürg Bernhard, Roswitha Kammler, Rudolf Maibach, Manuela Rabaglio-Poretti, Barbara Ruepp, Angelo Di Leo, Alan S Coates, Richard D Gelber, Meredith M Regan, Aron Goldhirsch, Marco Colleoni
PURPOSE: To evaluate endocrine activity in terms of ovarian function suppression (OFS) of degarelix (a gonadotropin-releasing hormone [GnRH] antagonist) versus triptorelin (a GnRH agonist) in premenopausal patients receiving letrozole as neoadjuvant endocrine therapy for breast cancer. PATIENTS AND METHODS: Premenopausal women with stage cT2 to 4b, any N, M0; estrogen receptor and progesterone receptor greater than 50%; human epidermal growth factor receptor 2-negative breast cancer were randomly assigned to triptorelin 3...
February 10, 2019: Journal of Clinical Oncology